These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33179309)

  • 1. Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy.
    Tohyama M; Asagi A; Nakasya A; Iuchi S; Hashine K
    J Dermatol; 2021 Feb; 48(2):215-218. PubMed ID: 33179309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
    Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
    BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
    Boeck S; Hausmann A; Reibke R; Schulz C; Heinemann V
    Anticancer Drugs; 2007 Oct; 18(9):1109-11. PubMed ID: 17704662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
    Stepanski EJ; Reyes C; Walker MS; Satram-Hoang S; Leon L; Wojtowicz-Praga S; Miller PJ; Houts AC; Schwartzberg LS
    Pancreas; 2013 Jan; 42(1):32-6. PubMed ID: 22699203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rash diagnosis: Gemcitabine-associated pseudocellulitis.
    Strouse C; Epperla N
    J Oncol Pharm Pract; 2017 Mar; 23(2):157-160. PubMed ID: 26946530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
    Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
    Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
    Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
    Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
    Fleming DR; Glisson SD; Bhupalam L; Michelson GD; Goldsmith GH; LaRocca RV
    Am J Clin Oncol; 2000 Aug; 23(4):349-52. PubMed ID: 10955861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
    Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
    Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
    Sumii T; Funakoshi A; Ito T; Mizumoto K; Tanaka M; Migita Y; Sakai T; Shinozaki H; Yamaguchi H; Niyahara T; Muranaka T; Eriguchi N; Ueki T;
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):971-6. PubMed ID: 12894712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases.
    Brandes A; Reichmann U; Plasswilm L; Bamberg M
    Anticancer Drugs; 2000 Jan; 11(1):15-7. PubMed ID: 10757558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
    Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single-center case series.
    Yahiro C; Takai T; Nakatani S; Tanaka N; Goto A
    J Dermatol; 2023 Mar; 50(3):357-363. PubMed ID: 36258256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
    Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
    Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
    World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-cisplatin: a schedule finding study.
    Kroep JR; Peters GJ; van Moorsel CJ; Catik A; Vermorken JB; Pinedo HM; van Groeningen CJ
    Ann Oncol; 1999 Dec; 10(12):1503-10. PubMed ID: 10643544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.